Aptorum Group Discloses Going Concern Doubt Amid Highly Dilutive Reverse Merger with DiamiR Biosciences
Summary
Aptorum Group has raised substantial doubt about its ability to continue as a going concern, while simultaneously announcing a highly dilutive reverse merger with DiamiR Biosciences where existing shareholders will retain only 30% of the combined entity.
Key Events
-
Going Concern Warning
Aptorum Group disclosed "substantial doubt" about its ability to continue as a going concern, citing a $1.06 million net loss and a $1.94 million working capital deficit for the nine months ended September 30, 2025.
-
Highly Dilutive Reverse Merger
The company plans an all-stock merger with DiamiR Biosciences Corp., resulting in existing Aptorum shareholders owning only approximately 30% of the combined entity, with DiamiR shareholders taking 70%.
-
Shift in Control
Post-merger, DiamiR's primary stockholders will gain significant influence over the combined company's board and key corporate decisions, including the ability to veto major corporate actions.
-
Recent Capital Infusion
Aptorum raised a total of $5.07 million in gross proceeds from two registered direct offerings in January and October 2025, providing essential capital amidst its financial challenges.
Analysis
Aptorum Group's disclosure of "substantial doubt" about its ability to continue as a going concern highlights severe financial distress, driven by significant net losses, a working capital deficit, and negative operating cash flow. This critical financial situation is being addressed through a proposed reverse merger with DiamiR Biosciences, which is highly dilutive for current Aptorum shareholders, who will own only 30% of the combined company. The terms of the merger also grant DiamiR's primary stockholders significant control over future corporate actions, including the ability to veto major decisions and influence executive appointments. While recent capital raises provide some liquidity, the fundamental shift in ownership and control, coupled with the ongoing financial challenges, presents a highly negative outlook for existing shareholders. Investors should monitor the progress of the merger and the company's ability to achieve financial stability post-transaction.
At the time of this filing, APM was trading at $0.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.69 to $4.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.